Silo Pharma (SILO) Projected to Release Earnings on Wednesday

Silo Pharma (NASDAQ:SILO) is expected to issue its results after the market closes on Wednesday, September 2nd. Analysts expect Silo Pharma to announce earnings of ($0.32) per share and revenue of $0.0180 million for the quarter.

Silo Pharma (NASDAQ:SILO) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.44). Silo Pharma had a negative net margin of 6,726.39% and a negative return on equity of 81.75%.

Silo Pharma Price Performance

SILO opened at $2.54 on Monday. Silo Pharma has a 12 month low of $2.43 and a 12 month high of $15.15. The stock has a market capitalization of $4.03 million, a price-to-earnings ratio of -0.58 and a beta of 0.71. The business has a fifty day moving average price of $4.57 and a 200 day moving average price of $5.40.

Analyst Ratings Changes

Separately, Weiss Ratings cut Silo Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Silo Pharma currently has an average rating of “Sell”.

Hedge Funds Weigh In On Silo Pharma

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in Silo Pharma by 134.6% during the 4th quarter. Geode Capital Management LLC now owns 92,905 shares of the company’s stock worth $32,000 after buying an additional 53,309 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Silo Pharma in the 3rd quarter valued at about $74,000. Finally, DRW Securities LLC acquired a new stake in shares of Silo Pharma during the 4th quarter worth about $113,000. Hedge funds and other institutional investors own 5.58% of the company’s stock.

Silo Pharma Company Profile

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.